A randomised, open-label, parallel group study to compare the pharmacokinetics and pharmacodynamics of NEODIDRO® 0.266 mg vs DIBASE® 25,000 IU oral doses in male and female patients.

2024-516252-17-00 Protocol CRC2024_01 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 9 Dec 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol CRC2024_01

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 48
Countries 1
Sites 1

Patients with low Vitamin D plasma level

Key facts

Sponsor
Centro Ricerche Cliniche Di Verona S.r.l.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
9 Dec 2025 → ongoing
Decision date (initial)
2024-12-02
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Patients with low Vitamin D plasma level

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Centro Ricerche Cliniche Di Verona S.r.l.

Sponsor organisation
Centro Ricerche Cliniche Di Verona S.r.l.
Address
Piazzale Ludovico Antonio Scuro 10
City
Verona
Postcode
37134
Country
Italy

Scientific contact point

Organisation
Centro Ricerche Cliniche Di Verona S.r.l.
Contact name
Stefano Milleri

Public contact point

Organisation
Centro Ricerche Cliniche Di Verona S.r.l.
Contact name
Stefano Milleri

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Italy Ongoing, recruiting 48 1
Rest of world 0

Investigational sites

Italy

1 site · Ongoing, recruiting
Centro Ricerche Cliniche Di Verona S.r.l.
U.O.C Reumatologia, Piazzale Ludovico Antonio Scuro 10, 37134, Verona

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Italy 2025-12-09 2025-12-15

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-14 Italy Acceptable with conditions
2024-12-02
2024-12-02
2 SUBSTANTIAL MODIFICATION SM-1 2024-12-18 Italy Acceptable
2025-02-19
2025-02-25
3 SUBSTANTIAL MODIFICATION SM-2 2025-06-30 Italy Acceptable 2025-08-26
4 SUBSTANTIAL MODIFICATION SM-3 2025-10-09 Italy Acceptable
2025-11-20
2025-11-26
5 NON SUBSTANTIAL MODIFICATION NSM-1 2025-12-22 Italy Acceptable
2025-11-20
2025-12-22